HAEMATO AG (HAEK.DE)
21.6 €
-0.60 (0.00%)
Rating:
Recommendation:
-
| Symbol | HAEK.DE |
|---|---|
| Price | 21.6 € |
| Beta | 1.262 |
| Volume Avg. | 0.00M |
| Market Cap | 112.953M |
| Shares () | - |
| 52 Week Range | 13.65-25.0 |
| 1y Target Est | - |
| DCF Unlevered | HAEK.DE DCF -> | |
|---|---|---|
| DCF Levered | HAEK.DE LDCF -> | |
| ROE | 6.51% | Neutral |
| ROA | 4.23% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 1.85% | Neutral |
| P/E | 11.68 | Strong Buy |
| P/B | 0.76 | Buy |
About
Download (Excel)Mr. Patrick Brenske
Healthcare
Drug Manufacturers—Specialty & Generic
Frankfurt Stock Exchange
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European imported drugs and medical products; and manufactures and distributes its generic drugs. It provides pharmaceuticals in the areas of oncology, HIV, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic medicine, as well as cosmetic products. The company also develops and markets medical devices and medical technology products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors, clinics, and medical laboratories. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.